Immunocore Holdings plc (IMCR)

Market Cap	1.57B +7.2%
Revenue (ttm)	400.02M +29.0%
Net Income	-35.51M
EPS	-0.71
Shares Out	50.70M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	268,469
Open	31.84
Previous Close	31.81
Day's Range	30.83 - 31.84
52-Week Range	24.61 - 40.72
Beta	0.83
Analysts	Buy
Price Target	61.82 (+99.1%)
Earnings Date	May 6, 2026

About IMCR

Immunocore Holdings plc, together with its subsidiaries, engages in the development and commercialization of immunomodulating medicines for patients with cancer, infectious diseases, and autoimmune disease in the United States, Europe, and internationally. The company offers KIMMTRAK for the treatment of unresectable or metastatic uveal melanoma. It also develops oncology programs, including tebentafusp which is in Phase 3 clinical trial for the treatment of advanced cutaneous melanoma and adjuvant uveal melanoma; brenetafusp which is in Phase ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Feb 5, 2021
• Employees: 524
• Stock Exchange: NASDAQ
• Ticker Symbol: IMCR
• Website: https://www.immunocore.com

Financial Performance

In 2025, Immunocore Holdings's revenue was $400.02 million, an increase of 28.95% compared to the previous year's $310.20 million. Losses were -$35.51 million, -30.48% less than in 2024.

Analyst Summary

According to 12 analysts, the average rating for IMCR stock is "Buy." The 12-month stock price target is $61.82, which is an increase of 99.10% from the latest price.

Price Target

$61.82

(99.10% upside)

Analyst Consensus: Buy